4Q 2023 Preliminary Unaudited Total Revenue of $72-74 Million FY 2023 Preliminary Unaudited Total Revenue of $256-258 Million FY 2024 and 2025 Total Revenue Guidance Increased to More than $320 Million and $370 Million, Respectively FY 2024 Net Income Expected to Exceed $60 Million and Adjusted EBITDA(1) Expected to be $85 Million Growth Opportunities Targeting Manufacturing and New Pipeline Hyperimmune Globulin to Advance During 2024 RAMSEY, N.J. and BOCA RATON, Fla., Jan. 08, 2024 (GLOBE NEWSWIRE) -- ADM ...

ADMA Biologics, Inc. (NASDAQ:ADMA) Q3 2023 Earnings Conference Call November 8, 2023 4:30 PM ET Company Participants Skyler Bloom - Head, Business Development & Corporate Strategy Adam Grossman – President & CEO Brian Lenz - EVP, CFO & GM, ADMA BioCenters Conference Call Participants Kristen Kluska - Cantor Fitzgerald Anthony Petrone - Mizuho Group Gary Nachman - Raymond James Operator Good afternoon, and welcome to the ADMA Biologics Third Quarter 2023 Financial Results and Corporate Update Conference Call ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission file number 001-36728 ADMA BIOLOGICS, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 56-2590442 (Sta ...

ADMA Biologics, Inc. (NASDAQ:ADMA) Q2 2023 Earnings Conference Call August 9, 2023 4:30 PM ET Company Participants Skyler Bloom - Senior Director, Business Development & Corporate Strategy Adam Grossman - Co-Founder, President, CEO & Director Brian Lenz - EVP, CFO & GM, ADMA BioCenters Conference Call Participants Gary Nachman - Raymond James & Associates Anthony Petrone - Mizuho Securities Kristen Kluska - Cantor Fitzgerald Operator Good afternoon, and welcome to the ADMA Biologics Second Quarter 2023 Fina ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission file number 001-36728 ADMA BIOLOGICS, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 56-2590442 (State or ...

ADMA Biologics, Inc. (NASDAQ:ADMA) Q1 2023 Results Conference Call May 10, 2023 4:30 PM ET Company Participants Skyler Bloom - Senior Director, Business Development and Corporate Strategy Adam Grossman - President and Chief Executive Officer Brian Lenz - EVP, Chief Financial Officer, General Manager of ADMA BioCenters Conference Call Participants Elliot Wilbur - Raymond James Anthony Petrone - Mizuho Securities Kristen Kluska - Cantor Fitzgerald Operator Good afternoon. And welcome to the ADMA Biologics Fir ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission file number 001-36728 ADMA BIOLOGICS, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 56-2590442 (State o ...

ADMA Biologics, Inc. (NASDAQ:ADMA) Q4 2022 Earnings Conference Call March 23, 2023 4:30 PM ET Company Participants Skyler Bloom - Senior Director of Business Development & Corporate Strategy Adam Grossman - Co-Founder, President, CEO & Director Brian Lenz - EVP, CFO & GM, ADMA BioCenters Conference Call Participants Anthony Petrone - Mizuho Securities Elliot Wilbur - Raymond James & Associates Kristen Kluska - Cantor Fitzgerald & Co. Operator Good afternoon, and welcome to the ADMA Biologics Fourth Quarter ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to _________ Commission File Number: 001-36728 ADMA BIOLOGICS, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 56-2590442 (State or Other Jur ...

ADMA Biologics, Inc. (NASDAQ:ADMA) Q3 2022 Earnings Conference Call November 9, 2022 4:30 PM ET Company Participants Skyler Bloom - Senior Director, Business Development & Corporate Strategy Adam Grossman - President & CEO Brian Lenz - EVP, CFO & General Manager, ADMA BioCenters Conference Call Participants Anthony Petrone - Mizuho Group Elliot Wilbur - Raymond James Kristen Kluska - Cantor Fitzgerald Operator Good afternoon, and welcome to the ADMA Biologics Third Quarter 2022 Financial Results and Corpora ...